Lyon, France, June 2022 – OREGA Biotech announces that IPH5201, a CD39-blocking monoclonal antibody partnered with AstraZeneca, will progress into a Phase 2 clinical trial in lung cancer.
“We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company.” — Jeremy Bastid, CEO
About IPH5201
OREGA Biotech initiated the CD39 program in 2010 and licensed it exclusively to Innate Pharma in 2016. AstraZeneca partnered the program in 2018 and conducted a Phase 1 dose-escalation trial in advanced solid tumours, testing IPH5201 alone or with durvalumab.